Zai Lab $ZLAB

Health Care · NASDAQ

China
$21.03
-0.89 (-4.06%)
As of Nov 20, 2026, 4:05 PM EST · cached
Price history
Loading chart…
Today's analyst average Analyst average over timeIndividual analyst targets Analyst history starts Oct 6, 2026, the first target we tracked for ZLAB.

Zai Lab (ZLAB) is trading down at $21.03 (-4.06%) on NASDAQ, as of the latest quote. It operates in the Health Care sector.

IPO: September 20, 2017 · $18.00 offering · NASDAQ

Analyst price targets on ZLAB

One firm's current price target on Zai Lab: $37 — 76% above the current $21. Each is tracked to its date and scored the same way a member's call is.

1 target, newest first. Open a row for its source and scoring.

DateOct 6, 2026 FirmCantor Fitzgerald RatingOverweight · reiterates Targetat $26.1 · $37 +42% Horizonby Oct 2027 StatusOpen

Entry price $26.1, the close nearest Oct 6, 2026, when the target was reported; the target is +42% from it.

Horizon No horizon stated, so it is tracked over the 12-month default, to Oct 2027.

Scoring Open: judged on the close on Oct 6, 2027.

Source Cantor Fitzgerald reiterates Zai Lab stock rating on ADC potential Investing.com · Oct 6, 2026 · opens the publisher's site
Cantor Fitzgerald reiterated an Overweight stock rating with a $37 price target on Zai Lab

Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. “At” is the closing price nearest the day the target was reported, the price we score it from; it is not an earlier target. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.

Zai Lab revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)
$460.2M−$122.2M−$704.5MFY2016 net income: −$37.5M'16FY2017 net income: −$50.4M'17FY2018 revenue: $129.0KFY2018 net income: −$139.1M · Net margin −107810.1%'18FY2019 revenue: $13.0MFY2019 net income: −$195.1M · Net margin −1502.3%'19FY2020 revenue: $49.0MFY2020 net income: −$268.9M · Net margin −549.3%'20FY2021 revenue: $144.3MFY2021 net income: −$704.5M · Net margin −488.2%'21FY2022 revenue: $215.0MFY2022 net income: −$443.3M · Net margin −206.1%'22FY2023 revenue: $266.7MFY2023 net income: −$334.6M · Net margin −125.5%'23FY2024 revenue: $399.0MFY2024 net income: −$257.1M · Net margin −64.4%'24FY2025 revenue: $460.2MFY2025 net income: −$175.5M · Net margin −38.1%'25−100%−50%0%50%FY2018 net margin: −107810.1% (off the scale, which stops at −100.0%)FY2019 net margin: −1502.3% (off the scale, which stops at −100.0%)FY2020 net margin: −549.3% (off the scale, which stops at −100.0%)FY2021 net margin: −488.2% (off the scale, which stops at −100.0%)FY2022 net margin: −206.1% (off the scale, which stops at −100.0%)FY2023 net margin: −125.5% (off the scale, which stops at −100.0%)FY2024 net margin: −64.4%FY2025 net margin: −38.1%
Zai Lab annual financial statements
FY2016Dec 2016FY2017Dec 2017FY2018Dec 2018FY2019Dec 2019FY2020Dec 2020FY2021Dec 2021FY2022Dec 2022FY2023Dec 2023FY2024Dec 2024FY2025Dec 2025
Income statement
Revenue——$129.0K$13.0M$49.0M$144.3M$215.0M$266.7M$399.0M$460.2M
Growth (year over year)———+9965.9%+277.0%+194.8%+49.0%+24.0%+49.6%+15.3%
Gross profit——$85.9K$9.24M$32.2M$92.1M$141.0M$170.9M$251.9M$269.6M
Gross margin——66.6%71.1%65.8%63.8%65.6%64.1%63.1%58.6%
Operating income−$38.5M−$51.4M−$141.8M−$203.2M−$301.8M−$700.1M−$404.4M−$366.6M−$282.1M−$229.4M
Operating margin——−109897.7%−1564.9%−616.4%−485.1%−188.0%−137.4%−70.7%−49.9%
Net income−$37.5M−$50.4M−$139.1M−$195.1M−$268.9M−$704.5M−$443.3M−$334.6M−$257.1M−$175.5M
Net margin——−107810.1%−1502.3%−549.3%−488.2%−206.1%−125.5%−64.4%−38.1%
EPS (diluted)−$3.97−$2.32−$2.64−$3.03−$0.35−$0.76−$0.46−$0.35−$0.26−$0.16
Balance sheet
Cash and equivalents$83.9M$229.7M$63.0M$75.9M$442.1M$964.1M$1.01B$790.2M$449.7M$679.6M
Total assets$88.9M$249.6M$302.0M$355.2M$1.30B$1.61B$1.22B$1.04B$1.19B$1.17B
Total liabilities$5.95M$14.5M$50.9M$60.5M$128.3M$230.0M$174.5M$240.2M$344.9M$456.9M
Shareholders' equity−$51.6M$235.2M$251.1M$294.7M$1.17B$1.38B$1.05B$796.1M$840.9M$715.5M
Cash flow
Operating cash flow−$32.2M−$32.4M−$97.5M−$191.0M−$216.1M−$549.2M−$367.6M−$198.2M−$214.9M−$150.8M
Capital expenditure$2.22M$9.10M$10.0M$6.04M$10.1M$18.3M$24.6M$7.21M$5.66M$8.10M
Free cash flow−$34.4M−$41.5M−$107.6M−$197.0M−$226.2M−$567.5M−$392.2M−$205.4M−$220.5M−$158.9M

From Zai Lab's 10-K, 10-Q, 20-F and 6-K filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. Per-share figures are per ordinary share, which is not always the share traded in the US: an ADS can stand for several, or for part of one. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Zai Lab in the news

Oct 6, 2026 Investing.com Cantor Fitzgerald reiterates Zai Lab stock rating on ADC potential Target

About Zai Lab

Headquarters
Shanghai, China From SEC filings, Oct 2026

More Health Care stocks

Browse all companies →